Quidel

News Release

Printer Friendly Version View printer-friendly version << Back
October 15, 2003 at 4:01 AM EDT

Quidel Third Quarter 2003 Conference Call Alert

SAN DIEGO--(BUSINESS WIRE)--Oct. 15, 2003--Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, will release 2003 third quarter results after market close on Wednesday, October 29, 2003, at 4:10 p.m. ET (1:10 p.m. PT).

S. Wayne Kay, president and chief executive officer, and Paul E. Landers, senior vice president and chief financial officer, will be hosting an investment-community conference call beginning at 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, October 29, 2003, to discuss those results and to answer questions.

To participate in the live call by telephone, please dial (888) 803-7396 from the U.S., or for international callers, please dial (706) 634-1052.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company's Web site at www.quidel.com. To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download and install the necessary audio software.

A replay will be available on Quidel's Web site for 14 days. A telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 3186368.

About Quidel

Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, Chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at http://www.quidel.com.

CONTACT: Quidel Corporation
Paul E. Landers, 858-552-7962
or
Lippert/Heilshorn & Associates
Ina McGuinness (imcguinness@lhai.com)
Bruce Voss (bvoss@lhai.com)
310-691-7100

SOURCE: Quidel Corporation